Aptinyx To Go Ex-Dividend On January 2nd, 2024 With 0.09869 USD Dividend Per Share
December 27th - $Aptinyx(APTX.US)$ is trading ex-dividend on January 2nd, 2024. Shareholders of record on December 26th, 2023 will receive 0.09869 USD dividend per share on December 29th, 2023. Th
Parkinson's Disease Psychosis Market Is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio
The dynamics of the Parkinson's disease psychosis market are anticipated to change in the coming years owing to the improvement in diagnosis methodologies, rising awareness of the disease, incrementa
Aptinyx Inc. (APTX) Witnesses Remarkable Recovery Amidst Challenges
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company specializing in brain and nervous system disorder treatments, is experiencing an astonishing after-market price surge. Despite a challenging day, the stock is making an epic recovery, soaring by an impressive 21% after hours. This unexpected jump is capturing attention and raising speculation about the factors driving Aptinyx ...
Short Interest in Aptinyx Inc. (NASDAQ:APTX) Decreases By 11.6%
Aptinyx Inc. (NASDAQ:APTX – Get Rating) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 2,890,000 shares, a decrease of 11.6% from the Marc
Aptinyx Inc. (NASDAQ:APTX) Expected to Post Q1 2024 Earnings of ($0.06) Per Share
Aptinyx Inc. (NASDAQ:APTX – Get Rating) – William Blair issued their Q1 2024 EPS estimates for Aptinyx in a research note issued on Friday, March 31st. William Blair analyst M. Minter forecasts tha
Stocks That Hit 52-Week Lows On Friday
 On Friday, 93 stocks made new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Canopy Gwth (NASDAQ:CGC) was the largest, in terms of market cap, to set a new 52-week low.Biodexa Pharmace
Aptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% Layoffs
In March, Aptinyx Inc (NASDAQ:APTX) completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disord
Aptinyx Q4 EPS $(0.18) Beats $(0.19) Estimate
Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 37.93 percent increase over losses of $(0.29) per s
Aptinyx 4Q Loss/Shr 18c >APTX
Aptinyx 4Q Loss/Shr 18c >APTX
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
12 Health Care Stocks Moving In Friday's Intraday Session
GainerselectroCore (NASDAQ:ECOR) shares increased by 27.9% to $5.47 during Friday's regular session. As of 13:30 EST, electroCore's stock is trading at a volume of 91.3K, which is 434.3% of its averag
Dermata DRMA Analyst; Aptinyx APTX EU Patent
Aptinyx Granted European Patent Titled 'Spiro-lactam Nmda Receptor Modulators And Uses Thereof (for The Treatment Of Conditions Such As Depression And Related Disorders)'
Aptinyx Granted European Patent Titled 'Spiro-lactam Nmda Receptor Modulators And Uses Thereof (for The Treatment Of Conditions Such As Depression And Related Disorders)'
HC Wainwright Lowers Aptinyx (NASDAQ:APTX) to Neutral
HC Wainwright cut shares of Aptinyx (NASDAQ:APTX – Get Rating) from a buy rating to a neutral rating in a report published on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for
Aptinyx (NASDAQ:APTX) Downgraded to Neutral at HC Wainwright
HC Wainwright cut shares of Aptinyx (NASDAQ:APTX – Get Rating) from a buy rating to a neutral rating in a research note published on Tuesday, The Fly reports. HC Wainwright also issued estimates for A
Equities Research Analysts' Downgrades for March 7th (ANIK, APTX, CDNA, CKN, CKNHF, COLL, E, EMBK, ETN, FMS)
Equities Research Analysts' downgrades for Tuesday, March 7th:Anika Therapeutics (NASDAQ:ANIK) was downgraded by analysts at Barrington Research from an outperform rating to a market perform rating.
Aptinyx Cut to Neutral From Buy by HC Wainwright & Co.
Aptinyx Cut to Neutral From Buy by HC Wainwright & Co.
HC Wainwright & Co. Downgrades Aptinyx to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aptinyx from Buy to Neutral.
Catalyst Biosciences CBIO Asset Purchase Deal; Aptinyx APTX Phase 2 Fail
Aptinyx APTX -68% Phase 2 PD Fail; Bioventus BVS +46% Settlement
No Data